Analyzing R&D Budgets: Johnson & Johnson vs Corcept Therapeutics Incorporated

R&D Investment: A Decade of Growth and Strategy

__timestampCorcept Therapeutics IncorporatedJohnson & Johnson
Wednesday, January 1, 2014183720008494000000
Thursday, January 1, 2015154190009046000000
Friday, January 1, 2016238440009095000000
Sunday, January 1, 20174037600010554000000
Monday, January 1, 20187524700010775000000
Tuesday, January 1, 20198901700011355000000
Wednesday, January 1, 202011476400012340000000
Friday, January 1, 202111386400014277000000
Saturday, January 1, 202213099100014135000000
Sunday, January 1, 202318435300015048000000
Monday, January 1, 202417232000000
Loading chart...

Unleashing the power of data

A Tale of Two R&D Giants: Johnson & Johnson vs. Corcept Therapeutics

In the ever-evolving landscape of pharmaceutical innovation, research and development (R&D) budgets are a critical indicator of a company's commitment to future growth. Over the past decade, Johnson & Johnson and Corcept Therapeutics have demonstrated contrasting approaches to R&D investment. From 2014 to 2023, Johnson & Johnson's R&D expenses surged by approximately 77%, reaching a peak of $15 billion in 2023. This reflects their robust strategy to maintain a competitive edge in the global market. In contrast, Corcept Therapeutics, a smaller player, increased its R&D spending by over 900% during the same period, highlighting its aggressive push to innovate and expand its niche offerings. While Johnson & Johnson's R&D budget dwarfs that of Corcept, the latter's rapid growth underscores the dynamic nature of the pharmaceutical industry, where even smaller companies can make significant strides.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025